Foghorn Therapeutics (FHTX) Invested Capital (2019 - 2025)
Foghorn Therapeutics has reported Invested Capital over the past 7 years, most recently at -$108.5 million for Q4 2025.
- For Q4 2025, Invested Capital fell 138.31% year-over-year to -$108.5 million; the TTM value through Dec 2025 reached -$108.5 million, down 138.31%, while the annual FY2025 figure was -$108.5 million, 138.31% down from the prior year.
- Invested Capital for Q4 2025 was -$108.5 million at Foghorn Therapeutics, down from -$89.7 million in the prior quarter.
- Over five years, Invested Capital peaked at $125.5 million in Q1 2021 and troughed at -$108.5 million in Q4 2025.
- A 5-year average of -$6.9 million and a median of -$26.4 million in 2023 define the central range for Invested Capital.
- Biggest five-year swings in Invested Capital: surged 223.97% in 2021 and later plummeted 69019.64% in 2023.
- Year by year, Invested Capital stood at $96.9 million in 2021, then crashed by 99.88% to $112000.0 in 2022, then plummeted by 69019.64% to -$77.2 million in 2023, then skyrocketed by 41.02% to -$45.5 million in 2024, then tumbled by 138.31% to -$108.5 million in 2025.
- Business Quant data shows Invested Capital for FHTX at -$108.5 million in Q4 2025, -$89.7 million in Q3 2025, and -$76.7 million in Q2 2025.